Confidently prescribe NUPLAZID® (pimavanserin) 34 mg, single capsule, for appropriate patients at the first sign of Parkinson’s disease (PD)-related delusions and hallucinations.1
The full therapeutic-level steady-state plasma concentration of NUPLAZID 34 mg was reached in 12 days with continuous treatment, without titration.1,2
Half-life (t1/2) is 57 hours1
Dosing and administration considerations1
For patients taking a strong CYP3A4 inhibitor, reduce the dosage of NUPLAZID to 10 mg daily
For patients taking a strong CYP3A4 inducer, monitor for reduced efficacy and consider increasing dosage of NUPLAZID
Avoid the use of NUPLAZID in patients with known QT prolongation or in combination with other drugs known to prolong QT interval
NUPLAZID does not require a dosage adjustment in elderly patients, in patients with mild to severe renal impairment or end-stage renal disease (ESRD), or in patients with hepatic impairment*
*Increased exposure (Cmax and AUC) to NUPLAZID occurred in patients with severe renal impairment (CrCl<30 mL/min, Cockcroft-Gault) in a renal impairment study. NUPLAZID should be used with caution in patients with severe renal impairment and ESRD.
NUPLAZIDconnect™ makes it easy to get patients started on treatment.